Sculptra and Restylane are on completely different clocks. A Restylane treatment puts volume in on the day you have it. Sculptra puts in a material that the body builds collagen around over the following weeks and months — you leave the first appointment with almost nothing to show.
That difference in timing is the whole decision. Sculptra is poly-L-lactic acid, or PLLA — a powdered biodegradable polymer mixed with sterile water before injection. The water is absorbed within days. What is left provokes a slow reaction in which fibroblasts lay down collagen around the particles. In its trials it was given as a course: up to four sessions about three weeks apart in the 2009 study, and an average of 3.6 sessions in the 2023 cheek study. The result you are paying for is not present for months.
Restylane is a family, and each product answers a different question on the day. Restylane and Restylane-L, Lyft, Silk, Refyne, Defyne, Kysse, Contour and Eyelight each hold their own FDA approval for their own area, and each has its own trial figures. Volume appears in the appointment, swelling settles over days, and what you see at two weeks is roughly what you have.
Only one of them can be undone. Hyaluronidase breaks hyaluronic acid down and does nothing to poly-L-lactic acid. If a Sculptra result is more than you wanted, the answer is time and, for a lump, saline and other measures — not an enzyme. The Sculptra labelling contains no statement about a reversal agent, because there is not one.
The vehicle it is mixed in gives a temporary plumpness that goes down within days as the water is absorbed. What is left is the material that will do the work.
Swelling and bruising then settle over about a week.
The current US labelling describes 367.5 mg of powder per vial, reconstituted with 5 mL or 8 mL. An older labelling format states 150 mg of poly-L-lactic acid as the polymer content; both figures circulate and they are not describing the same thing.
The 2009 nasolabial fold trial allowed up to four sessions about three weeks apart, with a maximum of 2.5 mL per fold per session. The 2023 cheek trial averaged 3.6 sessions, with a maximum of 9 mL per cheek per session.
Restylane trials generally allowed a single treatment with an optional touch-up a few weeks later.
There is no "time to visible change" endpoint in the approval documents. What exists is the treatment schedule, and it runs across months.
The primary endpoints were measured early: month 2 for Restylane Lyft in the cheeks, week 8 for Restylane in the lips.
The 2009 nasolabial fold trial ran a controlled phase to month 13 and an extension to month 25; 95 of the 106 people who entered the extension completed it, and their wrinkle scores stayed stable or improved. The 2023 cheek trial's primary endpoint was at month 12 - 70.7% of treated people improved by at least one grade on both cheeks against 25.9% of untreated controls - with 76.9% responders at months 21 and 24 in the previously treated extension group. Both trials were run by the manufacturer.
Restylane in lips: 59.3% still improved at week 24. Lyft in cheeks: 75.7% at month 12, against 57.4% in the untreated control group at the same visit. Kysse in lips: 60% at week 48. Eyelight under the eye: 63.5% at month 12. Defyne in the chin: 73.7% at week 48. Contour in cheeks: 62.8% at week 48.
The 2009 and 2023 approvals both specify people who are immune-competent.
Nasolabial folds and facial wrinkles: Restylane, Restylane-L, Lyft, Refyne, Defyne. Lips: Restylane, Restylane-L, Silk, Kysse. Cheeks: Lyft, Contour. Chin: Defyne, Lyft with Lidocaine. Back of the hands: Lyft. Under-eye hollows: Eyelight. Temples: Contour.
For a lump, the published options are saline infiltration, steroid injection, antibiotics if a biofilm is suspected, and surgery as a last resort.
In the US this is off-label use of the enzyme; dissolving filler is not one of its approved indications.
Sculptra's slow build has a practical consequence people underestimate. Because you cannot see the result of a session on the day, you cannot judge whether you have had enough — which is why the trials used fixed courses spaced weeks apart rather than treating to an endpoint. An injector who overfills on the day with a hyaluronic acid gel finds out immediately and can dissolve it. An injector who puts too much poly-L-lactic acid in finds out months later, and so do you.
The labelling asks patients to massage the treated area for five minutes, five times a day, for five days afterwards. That instruction is in the approved patient labelling. It has not been tested against not massaging in a controlled trial, so treat it as a labelled convention rather than a proven step — but it is what the label says.
Lumps are the characteristic problem with Sculptra and they can be late. In the 2009 nasolabial fold trial, papules or nodules occurred in 17.2% of the Sculptra group and 12.8% of the collagen control group. In the 2023 cheek trial, injection-site nodules were reported in 1.0% — one person, whose small palpable nodules were still present when the study finished. The reconstitution volumes used were not the same in those two eras, and higher dilution is the best-supported prevention measure, although the comparison supporting it is historical rather than randomised.
The labelling records the timing: nodules began at a median of 160 days and papules at a median of 55 days, with each lasting a median of about 100 to 110 days. Sculptra's labelling was updated in 2023 with information about delayed inflammation at the injection site following a viral or bacterial illness, vaccination or a dental procedure. If any of those are coming up, say so before you book.
Hyaluronic acid fillers have their own delayed nodules, at rates that differ by product and by clinic. The difference is what happens next: a hyaluronic acid nodule can be dissolved if conservative measures fail. A poly-L-lactic acid nodule cannot.
The only dated society figure is from 2023, the last year the American Society of Plastic Surgeons published filler fees: $901 for non-hyaluronic acid fillers, a group it defined as Radiesse, Sculptra, Bellafill and Renuva, against $715 for hyaluronic acid fillers. It is a per-procedure surgeon fee, not a per-vial price, and it hides the thing that matters most here: Sculptra is sold as a course of sessions, so one session's price is not the price of the treatment. There is no reliable published price for a full Sculptra course.
Go to an emergency department or call 911 for any of these after any injectable treatment:
Sudden change or loss of vision in either eye
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or blanched, then dusky, grey or mottled
Weakness, drooping, slurred speech or any stroke-like symptom
These can mean product has entered an artery, and the window is measured in hours. Sculptra makes this more urgent, not less. For a hyaluronic acid filler, high-dose hyaluronidase is the emergency treatment; for poly-L-lactic acid there is no equivalent, so speed of assessment is the only lever anyone has. Do not use pain as your gate — in a survey of experienced injectors describing their own intravascular injections, pain was mild or absent in 47% of events.
Swelling keeps increasing after the first few days instead of settling
A firm lump appears under the skin, whether at three weeks or at six months
Redness spreads outward from a treated area, or you develop a fever
An area becomes tender or swollen weeks later, particularly after an illness, a vaccination or dental work
One side starts to look different from the other as the result builds